To the full analysis
Ascendis Pharma stock: growth
ASNDAscendis Pharma reported $766.48M in revenue for fiscal 2025, up 90.2% on the prior year, up 150.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
33.9%
per year from 2012 to 2025, per share 17.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 150.9% | 56.0% | 33.9% |
| Revenue per share | 142.0% | 42.0% | 17.2% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $17.27M | $1.39M | −$1.04M |
| 2013 | $22.61M | $4.52M | $5.67M |
| 2014 | $15.49M | −$10.7M | −$20.84M |
| 2015 | $9M | −$36.48M | −$49.32M |
| 2016 | $5.1M | −$75.91M | −$67.43M |
| 2017 | $1.7M | −$137.29M | −$106.42M |
| 2018 | $11.72M | −$144.16M | −$156.74M |
| 2019 | $14.82M | −$241.58M | −$200.67M |
| 2020 | $7.7M | −$464.24M | −$324.78M |
| 2021 | $8.62M | −$425.04M | −$489.65M |
| 2022 | $56.71M | −$646.24M | −$565.34M |
| 2023 | $295.55M | −$533.49M | −$520.59M |
| 2024 | $402.95M | −$418.95M | −$340.88M |
| 2025 | $766.48M | −$242.71M | $48.34M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.